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Abstract: Recently, it has been demonstrated that oxygen free radicals have an important role 
as a signaling messenger in the receptor activator NFκB (RANK) signal pathway required for 
osteoclast differentiation. The aim of this study was to examine the potential of a strong free-
radical scavenger, water-soluble fullerene (C60), as a protective agent against the RANK-induced 
osteoclastogenesis and osteoclastic bone destruction in arthritis, both in vitro and in vivo. The 
effects of C60 on the RANK-induced osteoclastogenesis and osteoclastic bone resorption were 
examined in vitro. Adjuvant-induced arthritic rats were used as an animal model of arthritis. 
Rats were divided into two subgroups: control and treatment with C60 at 1.0 µM. The left ankle 
joint was injected intra-articularly with water-soluble C60 (20 µl) in the C60-treated group, 
while, as a control, the left ankle joint in the control rats received phosphate-buffered saline 
(20 µl) once weekly for eight weeks. Ankle joint tissues were prepared for histologic analysis. 
C60 significantly inhibited the responses of osteoclast precursor cells to RANK ligand, including 
osteoclast differentiation and osteoclastic bone resorption in vitro. In adjuvant-induced arthritic 
rats, intra-articular treatment with C60 in vivo reduced the number of osteoclasts and alleviated 
bone resorption and destruction in the joints, while control ankle joints showed progression of 
joint destruction with time. These findings indicate that C60 downregulates the RANK-induced 
osteoclast differentiation and is a potential therapeutic agent for inhibition of osteoclastic bone 
destruction in arthritis.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovitis 
involving synovial hyperplasia with neoangiogenesis and infiltration of lymphocytes 
and macrophages into the synovial tissue.1,2 Synovial hyperplasia erodes and destroys 
the bone and cartilage in the joint tissues of RA patients. In the joint of patients with 
RA, osteoclastic hyper-resorption is accelerated as the disease progresses.3 Recently, 
it was found that osteoimmunology, shared mechanisms, and crosstalk between the 
immune system and bone metabolism are closely involved in the pathogenesis of 
RA.4–7 Induction of osteoclast differentiation from precursor cells is known to be 
linked by receptor activator of NFκB (RANK)–RANK ligand (RANKL) signals.6 
When RANKL binds to RANK in an osteoclast precursor cell, RANKL–RANK 
signals are conveyed downstream to NFκB, P38, and others, provoking the induction 
of differentiation to osteoclasts.5,6 RANKL is expressed by synovial fibroblasts, acti-
vated T cells, and macrophages as well as osteoblasts and the expression is induced 
by proinflammatory cytokines including interleukin-1 (IL-1), IL-6, IL-17, and tumor International Journal of Nanomedicine 2009:4 234
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necrosis factor-α (TNF-α), which are implicated in the 
pathogenesis of RA.6–8
A series of recent reports have indicated that reactive 
oxygen species (ROS) play a critical role in osteoclast differ-
entiation initiated by RANK–RANKL signals.9–13 It has been 
already reported that several of the intracellular signals essen-
tial for osteoclast formation, including NFκB, c-Jun amino-
terminal kinase, PI3-kinase, and p38 MAPK, are sensitive to 
ROS.9–11 Osteoclast formation has been shown to depend on 
NFκB activation.7,9,13 It has been demonstrated that NFκB is a 
target for cellular activation by ROS9,12 and that antioxidants 
suppress NFκB activation in osteoclasts.13–15 Recent studies 
have clearly revealed that ROS mediates RANK–RANKL 
signaling in osteoclastogenesis.11–14 Lean and colleagues 
demonstrated that estrogen deficiency causes osteoclastic 
hyper-resorption by lowering antioxidant defenses in osteo-
clastic cells, thus entraining a ROS-mediated increase in 
osteoclastic differentiation and bone resorption.9 In addition, 
it has been demonstrated that systemic administration of 
antioxidants prevented the loss of bone that normally occurs 
with time in animal models.15 Therefore, targeting of ROS 
could have a distinct therapeutic value as a strategy to prevent 
osteoclastic hyper-resorption in arthritis.
Fullerene (C60) is composed of spherical carbon mol-
ecules with a unique cage structure.16,17 This compound has 
a high reactivity with oxygen free radicals and potential 
activity as a strong free-radical scavenger.18 It has been 
reported that the antioxidant level of C60 is several hundred-
fold higher than that of other antioxidants.18 Recently, C60 
derivatives have shown some remarkable biologic properties 
such as neural apoptosis,19 promotion of chondrogenesis,20 
and protection of skin keratinocytes from ROS-induced 
cell death after ultraviolet stress.21,22 We have already 
demonstrated that water-soluble C60 fullerene, a strong 
free-radical scavenger, can function as a protective agent 
against catabolic stress-induced degeneration of articular 
cartilage in a model of osteoarthritis in vitro and in vivo.23 
Water-soluble C60 significantly reduced articular cartilage 
degeneration in the osteoarthritis rabbit model. These find-
ings suggest that C60 has the potential to protect against 
oxygen free radical-induced pathological features in a 
variety of diseases. Exploitation of C60 could lead to the 
development of novel therapeutic strategies in the preven-
tion of both inflammation/synovitis and osteoclastic hyper-
resorption in RA.
In the present study, we investigated the influence of 
water-soluble C60 on generation of osteoclast differen-
tiation and osteoclastic bone resorption in order to explore 
any therapeutic or protective effect of C60 on the bone 
hyper-resorption in arthritis. We confirmed the suppressive 
effects of C60 on the RANK-induced osteoclast differentia-
tion and osteoclastic bone resorption in vitro. Our results 
indicated that intra-articular treatment with C60 significantly 
reduced bone resorption and joint destruction in adjuvant-
induced arthritic rats. These findings demonstrate that C60 
has suppressive effects on osteoclastic bone resorption and 
the resultant joint destruction in arthritis, suggesting that it 
could be useful for prevention and treatment of arthritis.
Patients and methods
effect of c60 on bone resorption in vitro
In arthritis, especially in RA, bone destruction progresses 
with advancing inflammation. We therefore examined 
whether C60 suppressed osteoclast differentiation and osteo-
clastic bone resorption in vitro. According to two very spe-
cific markers of authentic osteoclasts, we have thus defined 
multinucleated (more than or equal to three nuclei) tartrate-
resistant acid phosphatase (TRAP)-positive cells as mature 
osteoclasts, which could form resorption pits on dentine 
slices, verifying these cells as functional osteoclasts.
Influence of C60 on RANK-induced osteoclast 
differentiation in vitro
Poietic human osteoclast precursor cells were purchased 
from BioWhittaker Inc (Walkersville, MD, USA). To induce 
osteoclast differentiation in vitro, the osteoclast precursor 
cells were plated at a density of 5 × 104 cells per well in 
a final volume of 0.4 ml, using eight well chamber slides 
(Nalge Nunc International Corp, Naperville, IL, USA) and 
cultured in α-MEM supplemented with 10% heat-inactivated 
fetal calf serum (FCS), penicillin (50 U/ml), streptomycin 
(50 mg/ml), and 33 ng/ml M-CSF, at 37 °C in 5% CO2/95% 
air, in a humidified incubator. The cultures were further 
stimulated with 30 ng/ml soluble RANKL in the presence 
or absence of C60 (Vitamin C60 Inc., Tokyo, Japan; 0.1, 
1.0, or 10.0 µM). The cells were fed by replacing half the 
medium twice weekly with fresh stimuli. After seven days 
of culture, cells were fixed and stained for TRAP, using a 
commercial kit (Sigma, St. Louis, MO, USA) according to 
the manufacturer’s instructions.
TRAP staining was carried out as follows. After the 
incubation period, the medium was removed and wells 
were washed with 100 µL phosphate-buffered saline 
(PBS). Fixing solution (50 µL) was then added and the 
plate was centrifuged at room temperature for five minutes. 
After removing the fixing solution, the wells were washed International Journal of Nanomedicine 2009:4 235
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with 250 µL distilled diluted water (DDW) three times. 
Chromogenic substrate solution (50 µL) was added to each 
well and the plate was incubated at 37 °C for 20 minutes. 
When appropriate color developed, the chromogenic substrate 
solution was removed and the reaction was terminated in 
each well with 250 µL DDW. The wells were washed with 
DDW three times, then the surround was removed and the 
cells were mounted in water-soluble mounting agent (NUNK 
178599). The number of TRAP-positive multinucleated giant 
cells/field was counted under reflected light using a digital 
high fidelity microscope VH-8000 (x 200, Keyence Co, Ltd, 
Osaka, Japan).
effect of c60 on bone resorption by osteoclasts
The ability of osteoclasts to resorb pits was assessed by 
generating mature osteoclasts on ivory dentine slices 
(Wako Co, Ltd, Osaka, Japan) in 96 well plates. Osteo-
clast precursor cells were incubated in the presence or 
absence of C60 (0.1, 1.0, or 10.0 µM). After 14 days 
of culture, dentine slices were washed with phosphate-
buffered saline (PBS) and incubated for 18 hours in 0.25 M 
ammonium hydroxide, followed by sonication in PBS for 
30 seconds. Dentine slices were washed with PBS and 
stained in Mayer’s hematoxylin solution for two minutes, 
and pits were photographed under reflected light with a digi-
tal high fidelity microscope (VH-8000). The total pit areas 
were measured in four randomly selected areas of each 
dentine slice using an image analysis system (Image Gauge 
version 4.0, Fuji Photo Film Co, Ltd, Tokyo, Japan).
Efficacy of C60 in animal models 
of arthritis
We investigated whether C60 had any suppressive effects on 
arthritis (synovitis and joint destruction) using a rat arthritis 
model. Eight-week-old female SD rats were obtained from 
Charles River Laboratories Japan (Tokyo, Japan). Adjuvant-
induced arthritic rats were created as described in a previous 
report.24 The ankle joints of 40 rats were assessed. After being 
once immunized to produce arthritis, the rats were divided into 
a control group (n = 20 rats) and a C60-treated group (n = 20 
rats). In the control group, the left ankle joint was treated with 
an intra-articular injection of 20.0 µL PBS once per week for 
eight weeks, using a micro-needle syringe. In the C60-treated 
group, the left ankle joint was similarly treated with an intra-
articular injection of 20.0 µL C60 (10.0 µM) once per week 
for eight weeks. The right knee joints were not treated in either 
group to be compared to the contralateral ankle joints for the 
observation of arthritis development and progress.
The rats were euthanized at four and six weeks (n = 4 rats) 
after immunization and both ankle joints were harvested. Bone 
and cartilage tissue blocks were prepared for histological 
analysis. All experiments were conducted with the approval 
of the University Animal Care and Use Committee.
Articular bone and cartilage samples were fixed for two 
days in 4% paraformaldehyde solution and then decalcified 
in 4% paraformaldehyde containing 0.85% sodium chloride 
and 10% acetic acid. Tissues were dehydrated through a series 
of ethanol solutions and infiltrated with xylene before being 
embedded in paraffin and cut into 6-µm sections. Sections 
were deparaffinized through sequential immersion in xylene 
and a graded series of ethanol solutions in accordance with 
conventional procedures. The number of osteoclastic mul-
tinucleated giant cells/field was counted in six randomly 
selected bone areas in each sample under reflected light 
using a digital high fidelity microscope (VH-8000). Three 
independent observers assessed bone damage in a blinded 
manner.
In addition, the histological characteristic of bone tissue 
was scored by three blinded observers. Bone destruction 
was graded from 0 to 3, where 0 = normal, 1 = mild loss of 
cortical bone at few sites, 2 = moderate erosion of cortical 
and trabecular bone, and 3 = marked destruction of bone 
at many sites. Three independent observers assessed bone 
damage in a blinded manner.25
statistical analysis
Results are expressed as means ± standard deviations. 
Data were analyzed by a nonparametric statistical analysis. 
A P value  0.05 was considered statistically significant.
Student’s t-test was used to assess the differences between 
C60-treated and control groups with respect to arthritis and 
histologic parameters. When a statistically significant dif-
ference between the two groups was detected, analysis of 
variance (ANOVA) was used to adjust for the confounding 
effects of animals and observers.
Results and discussion
c60 inhibits osteoclast differentiation
To examine the inhibitory effect of C60 on osteoclast 
differentiation, the TRAP activity of the cells was observed 
during the differentiation of osteoclast precursor cells 
into osteoclasts. As shown in the representative images 
(Figure 1A), C60 at 10.0 µM inhibited the differentiation of 
osteoclast precursor cells into TRAP-positive multinucle-
ated giant cells. There was a significant difference in the International Journal of Nanomedicine 2009:4 236
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TRAP positivity between the control group and the 10.0 µM 
C60-treated group (Figure 1B).
c60 inhibits osteoclastic resorption
The activity of osteoclasts was assessed by examining their 
ability to form resorption lacunae on dentine slices. As 
shown in Figure 2A, C60 at 1.0 and 10.0 µM reduced the 
bone resorption area formed by the cells. There were sig-
nificant differences in bone resorption between the control 
and the C60-treated groups (Figure 2B; P  0.01: 0.1 µM 
C60-treated group, P  0.01: 1.0 µM C60-treated group).
Also, we performed the experiment to verify whether C60 
influenced the bone resorping activity of mature osteoclasts 
in vitro. After the maturation of osteoclasts, the pit formation 
assay was performed in the presence or absence of C60. As a 
result, in spite of the presence or absence of C60, there was no 
significant difference in the pit formation by the C60-treated 
mature osteoclasts in comparison with the control (mature) 
osteoclasts in the assay (data not shown). C60 did not influ-
ence the mature osteoclast activity, although C60 suppresses 
the differentiation of osteoclasts from the precursor cells. 
From the results, we concluded that inhibitory effect of 
C60 resulted from not the suppression of osteoclast activity 
but the reduced number of mature osteoclasts.
Pathological features of the arthritic 
rat model
Adjuvant-induced arthritic rats were administered C60 
(10.0 µM) once per week by intraarticular injection into the 
ankle joints during the development of arthritis. The severity 
of arthritis was monitored every two weeks after immuni-
zation. In the control joints, at the four-week and six-week 
time points, histologic features of arthritis were evident. 
These joints exhibited cartilage degeneration (extension 
of the area of surface fibrillation, chondrocyte clustering, 
abnormal deposition of chondrocytes and a decreased cell 
density with cartilage thinning), synovial hyperplasia with 
neoangiogenesis, infiltration of inflammation-related cells 
into the synovial tissue, and bone resorption/destruction by 
multinucleated osteoclastic cells of the subchondral bone 
and areas of exposed bone. In contrast, treatment of the 
ankle joints with C60 markedly inhibited synovitis, such as 
synovial hyperplasia and infiltration of inflammation-related 
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Figure 1 Inhibitory effects of c60 on the osteoclastogenesis. Osteoclast precursor cells were incubated with osteoclast differentiation factors in the presence or absence of 
water-soluble c60 (0.1, 1.0, or 10.0 µM) for seven days. Data from four independent experiments were analyzed. A) At the end of incubation period, the osteoclastogenesis 
was analyzed by the tartrate-resistant acid phosphatase (TRAP) staining. Representative images A) showed that c60 at 10.0 µM inhibited the differentiation of osteoclast pre-
cursor cells into TRAP-positive multinucleated giant cells. B) There was a significant difference in the TRAP positivity between the control group and the 10.0 µM c60-treated 
group (P  0.01 compared to the control).International Journal of Nanomedicine 2009:4 237
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cells, and joint destruction in the adjuvant-induced arthritic 
rats (data not shown).
Although the levels of expression of osteoclastic cells and 
bone erosion in the joints progressed with time in both con-
trol and C60-treated groups, the C60-treated group showed 
significantly lower levels at four weeks and six weeks to the 
respective control group (Figures 3A, B, C).
C60 had suppressive effects both on osteoclast differen-
tiation and bone resorption, which leads to the possibility 
of C60 being beneficial in osteoporosis. RA patients often 
have juxta-articular osteoporosis as well as systemic 
osteoporosis.1–3 Our findings suggest that C60 is expected 
to exert a beneficial effect on juxta-articular osteoporosis by 
dual mechanisms, both direct and indirect. One is a direct 
suppressive effect on osteoclast differentiation in that C60 
inhibits the RANK–RANKL signal by removal of ROS, a 
messenger of the signal pathway. Recent studies have clearly 
revealed that ROS mediates RANK-RANKL signaling 
in osteoclastogenesis.9–15 We confirmed in vitro that C60 
significantly suppressed osteoclast differentiation in vitro. 
This suppressive effect is considered to be exerted at the step 
of differentiation of precursor cells into osteoclasts. Another 
is the indirect or secondary effect exerted by suppressing the 
production of proinflammatory cytokines which can enhance 
the intensity of the RANK–RANKL signal. TNF-α, IL-1, 
IL-6, and IL-17 are also called bone resorptive cytokines 
and are known to accelerate bone resorption.22 There is 
general consensus that ROS is increasingly produced from 
inflammation-related cells in parallel with the stimulation 
by proinflammatory cytokines such as TNF-α, IL-1, IL-6, 
and IL-17 and plays an important role as a messenger of the 
intracellular signal pathways.26,27 The present study sought 
to demonstrate in vitro and in vivo that water-soluble C60 
fullerene can function as a protective agent against the bone 
resorption/destruction occurring in arthritis. Our in vitro stud-
ies indicate that water-soluble C60 inhibits the differentiation 
of osteoclast precursor cells into osteoclasts and osteoclastic 
bone resorption.
In conclusion, our findings indicate that water-soluble 
C60 fullerene can function as a protective agent against 
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Figure 2 Inhibitory effect of c60 on osteoclastic bone resorption in vitro. A) Osteoclast precursor cells were incubated with osteoclast differentiation factors in the presence 
or absence of c60 (0.1, 1.0, or 10.0 µM).   At the end of the incubation period, the ability of osteoclasts to resorb pits was assessed by the total pit areas on ivory dentine slices. 
Data from four independent experiments were analyzed.   As the representative images, c60 (1.0 and 10.0 µM) inhibited the pit formation resorted by the cells. B) There were 
significant differences in bone resorption between the control and the C60-treated groups (P  0.01: 1.0 µM c60-treated group, P  0.01: 10.0 µM c60-treated group).International Journal of Nanomedicine 2009:4 238
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osteoclastogenesis and the resultant bone hyper-resorption 
in vitro. Intra-articular treatment with this compound signifi-
cantly reduces osteoclastic bone destruction in the rat model 
of arthritis. These findings suggest that C60 fullerene may be 
useful as a therapeutic agent for bone resorption in arthritis.
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